

MTWA Reimbursement in Japan

Microvolt T-Wave Alternans™ (MTWA) test received reimbursement coverage from Japan's Ministry of Health, Labor and Welfare (MHLW). Effective April 1, 2012, the MTWA Test will be reimbursed for patients who are considered at risk for lethal arrhythmias including, but not limited to, patients with a history of heart attack, cardiomyopathy and Brugada syndrome. Commenting on the decision, Dr. Takanori Ikeda, Professor of Medicine at Toho University Medical Center, said, "We are very pleased with the reimbursement decision on MTWA testing. A large body of clinical evidence supports the predictive value of the test which can now be used more broadly to help identify and manage the risk of life-threatening arrhythmias."